Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
about
Virus-specific CD4+ T cells eliminate borna disease virus from the brain via induction of cytotoxic CD8+ T cellsComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesHyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsStructural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 InfectionCrystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 InteractionDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingFine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.Persistent infection of macaques with simian-human immunodeficiency virusesSurvivors Remorse: antibody-mediated protection against HIV-1.Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.Evolving virus plagues.Evidence for heterogeneous selective pressures in the evolution of the env gene in different human immunodeficiency virus type 1 subtypes.Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusionEpitope target structures of Fc-mediated effector function during HIV-1 acquisition.Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.Phages and HIV-1: from display to interplay.Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoproteinIdentification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmissionBroad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
P2860
Q24523159-9BE5B704-4A26-47DA-91D7-C88F48102628Q24561905-D45C7D29-D04A-41C9-A076-925C82E36652Q24679395-8DEAB4B9-6CAF-4219-9704-EEE35E36A54CQ26782237-942D2F7F-603E-4B3E-8896-8BD373BDFFB3Q27320687-06918E33-D7D2-4763-8234-D94FE730245FQ27640572-E2DAB91F-6D08-450F-9E15-949BBC13136CQ27661588-417C9FC7-602E-4823-94DD-C2DAE0EDA155Q27675486-D618A741-A84F-4CCA-BEBB-E9A2B8DC17B6Q28217208-58A47048-5CE7-4452-A9CB-985804F51CC3Q28775731-89106262-881D-462D-BBAA-5D31BB9163AAQ30238730-19B747E0-623D-47B1-9DD5-5EB1BA56E7D4Q30358769-25D114BC-8F84-4F26-A816-7B5E92BDBD5BQ31143293-BF870AD1-827D-4D7D-87B2-258D3ABA35DCQ33305012-B37698B2-2D0B-472C-88A4-ABD2A3093D44Q33560538-6B0116B4-9598-4AD1-9C67-0A2D46D5F774Q33717659-7671A413-B584-4356-BFA8-955745A181E5Q33737656-72FB8D61-DF44-4E43-A1B0-903E49E42A91Q33782007-CD1A3924-810D-43A3-AA15-A05B9BB462D2Q33785473-28A9A4A0-B5EC-4BAC-BD15-43B182CF0D96Q33785510-00896CFD-22B4-472D-9BCD-54D120C8EF49Q33786382-4BA5CC8D-DD3D-4216-B43A-72363C9B9BCCQ33794954-A0BC34EF-B2C9-4A12-8547-1AE80AFD22BEQ33813212-FA88EBC6-15AC-45DE-8D48-1C94C1BB1F9FQ33813526-87EF23FF-548C-49AC-807E-94E4BFE6F8C0Q33821896-CA449CCB-2C7E-4526-A2C6-9BDDB0451A93Q33842152-FDD132C3-39B4-4D4A-B5BF-3DC510283050Q33849237-DC522C44-DA76-4FC1-8E2F-773934EAC7BEQ33924272-E469B736-D3B8-4062-BC13-93E21C35A8A6Q34045535-2971E135-0842-444F-A391-18FB8719F042Q34172295-32E822AC-332D-4FD8-AB78-97E0E8A0CB5BQ34273397-7A8F4F27-C5B3-4F4E-82A4-AF0D5590FEECQ34347265-6AAB585C-997B-4BE2-9180-36BF48D24C42Q34428738-E0551802-E17F-4639-ABA5-D0721BC167B2Q34545861-1BE966C4-3292-4E89-B94C-A5389567479BQ34885869-B14E6167-6977-457D-8A7F-E1BE7569A9A0Q35227014-817588DD-2229-473D-99AD-6247EF7D702FQ35488153-EB7E8916-2A4B-4AEC-A488-2A0386C9B328Q35785010-3CCA14E8-7681-4D6F-A638-F21EE114B451Q35828898-057E2B01-5F9C-4DB8-8531-7B6784353756Q35833324-FF710D4D-71B2-4144-BD9D-0FFCB20394EB
P2860
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Exploration of antigenic varia ...... y using monoclonal antibodies.
@ast
Exploration of antigenic varia ...... y using monoclonal antibodies.
@en
type
label
Exploration of antigenic varia ...... y using monoclonal antibodies.
@ast
Exploration of antigenic varia ...... y using monoclonal antibodies.
@en
prefLabel
Exploration of antigenic varia ...... y using monoclonal antibodies.
@ast
Exploration of antigenic varia ...... y using monoclonal antibodies.
@en
P2093
P2860
P1433
P1476
Exploration of antigenic varia ...... y using monoclonal antibodies.
@en
P2093
F E McCutchan
P2860
P304
P407
P577
1994-12-01T00:00:00Z